Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.65	$3.31	$2.70 ▼ $4.72	$699.71M	0.86	874,110 shs	748,142 shs
GHRS GH Research	$13.63 +1.8%	$13.91	$6.00 ▼ $20.50	$709.17M	0.98	335,144 shs	219,393 shs
KALV KalVista Pharmaceuticals	$13.59 +3.3%	$13.42	$7.30 ▼ $16.32	$684.12M	0.05	780,105 shs	342,039 shs
TVGN Tevogen Bio	$0.92 -0.1%	$1.09	$0.26 ▼ $3.09	$180.95M	-0.77	1.40 million shs	398,002 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+4.29%	+4.58%	+13.35%	+7.04%	-5.68%
GHRS GH Research	+1.59%	+6.69%	-7.66%	+6.52%	+21.29%
KALV KalVista Pharmaceuticals	+1.31%	+2.73%	-9.74%	+15.44%	+0.77%
TVGN Tevogen Bio	+0.11%	-1.04%	-13.11%	-29.69%	+69.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.6884 of 5 stars	3.5	1.0	0.0	3.6	2.5	0.6
GHRS GH Research	1.7824 of 5 stars	3.4	3.0	0.0	1.6	0.8	0.0
KALV KalVista Pharmaceuticals	3.7907 of 5 stars	3.6	1.0	4.4	2.5	0.8	0.6
TVGN Tevogen Bio	3.8485 of 5 stars	3.5	3.0	0.0	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	50.68% Upside
GHRS GH Research	2.88	Moderate Buy	$32.00	134.78% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	93.42% Upside
TVGN Tevogen Bio	3.00	Buy	$10.00	987.07% Upside

Current Analyst Ratings Breakdown

Latest TVGN, ABUS, GHRS, and KALV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/13/2025	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
8/4/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	113.40	N/A	N/A	$0.43 per share	8.49
GHRS GH Research	N/A	N/A	N/A	N/A	$5.83 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($0.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.29	N/A	N/A	N/A	-352.24%	-59.28%	-44.11%	11/5/2025 (Estimated)
GHRS GH Research	-$38.96M	-$0.74	N/A	N/A	N/A	N/A	-16.71%	-16.06%	9/2/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)
TVGN Tevogen Bio	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-775.49%	11/10/2025 (Estimated)

Latest TVGN, ABUS, GHRS, and KALV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2025	Q1 2026	KALV KalVista Pharmaceuticals	-$0.91	N/A	N/A	N/A	$1.97 million	N/A
9/2/2025	Q2 2025	GHRS GH Research	-$0.22	N/A	N/A	N/A	N/A	N/A
8/19/2025	N/A	TVGN Tevogen Bio	-$0.05	-$0.03	+$0.02	-$0.03	N/A	N/A
8/7/2025	Q2 2025	GHRS GH Research	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
8/6/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	$0.01	+$0.03	$0.01	$2.21 million	$10.74 million
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	20.53	20.53
GHRS GH Research	N/A	29.49	29.49
KALV KalVista Pharmaceuticals	N/A	5.35	5.35
TVGN Tevogen Bio	N/A	0.26	0.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
GHRS GH Research	56.90%
KALV KalVista Pharmaceuticals	N/A
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
GHRS GH Research	N/A
KALV KalVista Pharmaceuticals	4.30%
TVGN Tevogen Bio	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.70 million	152.78 million	Optionable
GHRS GH Research	10	52.03 million	N/A	Optionable
KALV KalVista Pharmaceuticals	100	50.34 million	48.18 million	Optionable
TVGN Tevogen Bio	3	196.71 million	52.64 million	N/A

TVGN, ABUS, GHRS, and KALV Headlines

Recent News About These Companies

Tevogen Bio Holdings Inc. Highlights Internally Developed Assets Reflecting Long-Term Value

3 hours ago | quiverquant.comQ

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

3 hours ago | globenewswire.com

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

August 26 at 5:28 PM | markets.businessinsider.com

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

August 26 at 2:50 PM | globenewswire.com

Tevogen Bio Holdings Inc. Reports 24% Increase in Institutional Ownership in Q2 2025

August 25 at 3:51 PM | quiverquant.comQ

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

August 25 at 3:10 PM | globenewswire.com

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

August 22, 2025 | markets.businessinsider.com

Tevogen Bio Holdings Inc. Recognized in BINJE's BEST Health Care 2025 for Commitment to Health Equity and Innovation

August 22, 2025 | quiverquant.comQ

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

August 22, 2025 | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results

August 21, 2025 | marketbeat.com

D. Boral Capital Reiterates Buy Rating for Tevogen Bio (NASDAQ:TVGN)

August 20, 2025 | marketbeat.com

Tevogen finalizes agreement for up to $50M in financing

August 19, 2025 | msn.com

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance ...

August 19, 2025 | bakersfield.comB

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

August 19, 2025 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Q2 2025 Financial Results with Reduced Loss from Operations and Focus on Growth Strategy

August 19, 2025 | quiverquant.comQ

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

August 19, 2025 | globenewswire.com

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

August 18, 2025 | globenewswire.com

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

August 18, 2025 | globenewswire.com

Semper Paratus Acquisition (NASDAQ:TVGN) Stock Price Down 3% - Here's What Happened

August 16, 2025 | marketbeat.com

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

August 14, 2025 | globenewswire.com

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

August 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, ABUS, GHRS, and KALV Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.65 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$3.66 +0.02 (+0.41%)

As of 05:37 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

GH Research NASDAQ:GHRS

$13.63 +0.24 (+1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$13.58 -0.05 (-0.40%)

As of 04:39 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

KalVista Pharmaceuticals NASDAQ:KALV

$13.59 +0.43 (+3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$13.63 +0.04 (+0.26%)

As of 05:29 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Tevogen Bio NASDAQ:TVGN

$0.92 0.00 (-0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$0.91 -0.01 (-0.64%)

As of 05:26 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time